Cancer is a complex disease involving multiple oncogenes with diverse actions. Inhibiting only one oncogene is unlikely to eliminate the malignancy of cancer cells. The goal of this study was to investigate whether synergistic effects can be achieved by combined silencing of two oncogenes, K-ras and Akt2, which are key players in the Ras/MAPK and PI3K/Akt signaling pathways. The pancreatic cancer cell line, Panc-1, was selected for these studies as it has elevated expression of K-ras and Akt2. Compared with inhibiting each oncogene alone, simultaneously silencing the two oncogenes with RNA interference (RNAi) more effectively inhibited Panc-1 cell proliferation and colony formation, induced a significantly higher percentage of apoptosis and resulted in greater inhibition of c-myc expression in vitro. Furthermore, when delivered by polyethyleneimine into Panc-1 tumors in nude mice, RNAi simultaneously targeting K-ras and Akt2 inhibited tumor growth more efficiently than RNAi targeting the individual oncogenes. Therefore, RNAi simultaneously silencing the oncogenes K-ras and Akt2 may offer potential opportunities for pancreatic cancer gene therapy.
Introduction
Cancer is a complex disease characterized by multiple genetic and molecular alterations affecting a variety of cellular processes, including proliferation, survival and invasion. 1 Although many of these alterations are potential targets for the development of new anticancer therapeutics, it is unlikely that inhibiting only one target will eliminate the malignancy of cancer cells. Rather, strategically combined inhibition of multiple critical targets might offer more effective therapeutic benefits.
Pancreatic adenocarcinoma is the fourth leading cause of cancer death in both men and women in the United States. 2 Despite recent advances in the management of this disease, the development of new therapeutic strategies is critical. 3 Although the disease mechanism is not understood, two key signaling pathways have been implicated in pancreatic adenocarcinoma pathogenesis: Ras/MAPK and PI3K/Akt. A mutation in codon 12 of the K-ras oncogene, which is present in the early stages in more than 85% of pancreatic cancer specimens, results in constitutive activation of the MAPK signaling pathway and enhances the proliferation of pancreatic cancer cells. [4] [5] [6] [7] Expression of K-ras in pancreatic cancer cells seems to contribute primarily to early stages of cancer initiation, whereas it does not seem to have a critical role in the later stages. 8 The PI3K/Akt pathway is critical in late stage progression of cancer. Once activated, this pathway promotes cancer cells to proliferate and evade programmed cell death. 9 The oncogene Akt2 is associated with the development of human cancers, and its overexpression is observed in about 20% of all cases of pancreatic ductal adenocarcinoma. 10 As the Ras/MAPK and PI3K/Akt pathways play different and vital roles in the pathogenesis of pancreatic cancer, we hypothesize that simultaneously silencing the oncogenes K-ras and Akt2 to target both signaling pathways may effectively inhibit cancer cells. We tested this hypothesis in a pancreatic cancer cell line (Panc-1) by silencing target genes using RNA interference (RNAi).
Materials and methods
Tumor cell lines and culture condition Human pancreatic cancer cell lines, including Panc-1, MIAPaCa-2, AsPC-1 and BxPC-3 were obtained from American Type Culture Collection (Rockville, MD, USA), and P1, P2, P3, P4 and P7 cell lines were constructed by our laboratory. 11 All cells, except MIAPaCa-2, were maintained in culture with RPMI1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Gemini Bio-Products, Woodland, CA, USA) at 37 1C in a humidified atmosphere containing 5% CO 2 . MIAPaCa-2 cells were cultured with Dulbecco's Modified Eagle's Medium (DMEM).
Plasmid construction Linearized pcDNA 6.2-GW/EmGFP-miR vector was purchased from Invitrogen. This vector can express short interfering RNA (siRNA) in most mammalian cells using the human cytomegalovirus immediate early promotor. The vector also expresses EmGFP (emerald green fluorescent protein), and the siRNA insertion site is in the 3 0 untranslated region of the EmGFP mRNA. Herpes simplex virus thymidine kinase is the termination signal. Criteria for the selection of the target sequence: (i) The target sequence should be 21 nt in length; (ii) Make sure that the target sequence does not contain runs of more than three of the same nucleotide; (iii) Choose a sequence with low to moderate GC content (B30-50% GC content is suggested); (iv) Do not choose a target sequence that is a known site for RNA-protein interaction; (v) Avoid some restriction sites (that is, BamHI, BglII, SalI, XhoI, DraI and MscI), which may be used for optional, advanced features later; (vi) Make sure that the target sequence does not contain significant homology to other genes as this can increase off-target RNAi effects and (vii) Choose a target sequence encoding the sense sequence of the target mRNA. The target sequences were not previously demonstrated to have RNAi effects. The siRNA produced by the vector fully complements their target site and cleaves the target mRNA. There are two loops in the sequence of the oligos, a 19-nt spacer (GTTTTGGCCACTGACTGAC) to form the terminal loop, and 2 nt (the ninth and tenth nucleotides of the sense target sequence) are removed to create an internal loop, and they are marked out by italic in the following sequences. The first recombinant plasmid (anti-ras) was designed to inhibit the oncogene K-ras (NM_004985.3) in the Panc-1 cell line. The annealed oligos ligated into the pcDNA 6.2-GW/EmGFP-miR plasmid vector were:
Top strand: 5-TGCTGTCCTGTAGGAATCCTCTAT TGGTTTTGGCCACTGACTGACCAATAGAGTTCCTA CAGGA-3 and bottom strand: 5-CCTGTCCTGTAG GAACTCTATTGGTCAGTCAGTGGCCAAAACCAATA GAGGATTCCTACAGGAC-3.
The second recombinant plasmid (anti-akt2) was designed to inhibit the oncogene Akt2 (NM_001626.3) in Panc-1 cells. The annealed oligos ligated into pcDNA 6.2-GW/EmGFP-miR plasmid vector were:
Top strand: 5-TGCTGTTGCCAAGGAGTTTGAGA TAGGTTTTGGCCACTGACTGACCTATCTCACTCCT TGGCAA-3 and bottom strand: 5-CCTGTTGCCAAG GAGTGAGATAGGTCAGTCAGTGGCCAAAACCTAT CTCAAACTCCTTGGCAAC-3.
The third and fourth recombinant plasmids (anti-k þ a and anti-a þ k) were constructed to simultaneously inhibit K-ras and Akt2 oncogenes in Panc-1 cells. The vector contained the two siRNAs in tandem to express them in a single primary transcript, thus ensuring co-cistronic expression of multiple siRNAs. So we were able to construct vectors that can inhibit the two targeted oncogenes simultaneously. The last recombinant plasmid (negative plasmid) contained sequences not predicted to target any known vertebrate gene. The annealed oligos ligated into pcDNA 6.2-GW/EmGFP-miR plasmid vector were:
Top strand: 5-TGCTGAAATGTACTGCGCGTGGA GACGTTTTGGCCACTGACTGACGTCTCCACGCAGT ACATTT-3 and bottom strand: 5-CCTGAAATGTACT GCGTGGAGACGTCAGTCAGTGGCCAAAACGTCTC CACGCGCAGTACATTTC-3.
Plasmid construction was performed following the manufacturer's instructions.
Transient and stable transfection
For all experiments, cells were used in exponential growth phase. After an attachment period of 24 h, cells were transiently transfected with anti-ras, anti-akt2, anti-k þ a, anti-a þ k, and negative plasmid using Lipofectamine2000 reagent (Invitrogen, Frederick, MD), according to the manufacturer's guidelines. Optimization revealed that using 3 mg plasmid and 6 ml Lipofectamine2000 in six-well plates achieved optimal results. For stable transfection, Lipofectamine2000 was used to transfect all the plasmids into cells in six-well plates. At 6 h after transfection, the media were removed and replaced with fresh growth medium. Cells were incubated overnight at 371C. The following day, cells were trypsinized and replated into 10 cm plates in a medium containing blasticidin (4 mg ml
À1
; Invitrogen, Frederick). Media were replaced with fresh medium containing blasticidin every 3-4 days until blasticidin-resistant colonies were identified. Blasticidin-resistant colonies were picked and assayed for target gene knockdown.
Quantitative real-time PCR analysis
Total RNA was extracted from 10 6 treated or untreated pancreatic cancer cells using the Absolutely RNA Miniprep kit (BioFlux, Beijing, China), according to the manufacturer's instructions. Reverse transcription reactions were carried out using 5 mg of total RNA and the Super Script III First Strand cDNA synthesis kit, according to the manufacturer's instructions (Invitrogen). All cDNA samples were aliquoted and stored at À70 1C for further use. Real-time PCR was performed on the 7500 Real-Time System (ABI) using the SYBR Green qPCR kit (ABI) and gene-specific primers. Primers designed for detecting K-ras mRNA were:
Sense, 5-GACTCTGAAGATGTACCTATGGTCCTA-3 and antisense, 5-CATCATCAACACCCTGTCTTGTC-3.
Primers designed for detecting Akt2 mRNA were: Sense, 5-CCCCCTTAAACAACTTCTCCG-3 and antisense, 5-CATCCACTCCTCCCTCTCGTC-3.
As a control, GAPDH mRNA was also detected using the following primers: sense, 5-GCACCGTCAAGGCTG AGAAC-3 and antisense, 5-GCCTTCTCCATGGTGGT GAA-3.
For amplification, the following program was employed: 2 min at 50 1C, 10 min at 95 1C, followed by 40 cycles of 15 s at 95 1C and 1 min at 60 1C. The semiquantitative comparison between samples was calculated as follows: the data were normalized by subtracting the difference of the threshold cycles (C t ) between the gene of interest's C t and GAPDH's C t (gene of interest C t ÀGAPDH C t ¼ DC t ) for each sample. The DC t was then compared with the expression levels of the vector control sample.
Western blot analysis
Transfected cells were lysed on ice in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerol and 1% Triton X-100) containing 1 Â complete protease inhibitor (Roche Diagnostics GmbH, Mannheim, Germany). To study protein phosphorylation, the buffer was additionally supplemented with 1 mM NaVO 4 , 10 mM NAF and 10 mM b-glycerophosphate. Lysates were heat denatured at 100 1C for 10 min before being run on 12% SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Millipore UK Ltd, Winchester, UK). Membranes were blocked in 5% bovine serum albumin in tris-buffered saline Tween-20 buffer (10 mM Tris, pH 7.6, 150 mM NaCl and 0.1% Tween-20) and probed with primary antibody in tris-buffered saline Tween-20 þ 5% bovine serum albumin at recommended dilutions. Primary antibodies included K-ras (Ab-2) (CN Biosciences UK Ltd, Nottingham, UK); Akt2 antibody (Cell Signaling Technology, Beverly, MA) and GAPDH antibody (Abcam, Cambridge, MA); phospho-ERK, phospho-GSK, caspase-3a/b and c-myc (Santa Cruz Biotechnology Inc., Santa Cruz, CA). Membranes were incubated in secondary antibody (Santa Cruz Biotechnology Inc) diluted in tris-buffered saline Tween-20 þ 5% bovine serum albumin for 60 min. The signal was detected by the enhanced chemiluminescence system (Amersham Pharmacia Biotech, Bucks, UK) and BioMax MR-1 radiographic film (Kodak, Xiamen, China).
CCK-8 assay
Cell counting kit-8 (CCK-8) (Dojindo Laboratories, Kumamoto, Japan) allows convenient assays by utilizing highly water-soluble tetrazolium salt. WST-8 (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt) produces a water-soluble formazan dye on reduction in the presence of an electron mediator. Stably transfected cells containing anti-ras, anti-akt2, anti-k þ a and negative plasmid were seeded in a 96-well plate (1000 cells per well). The following day, the media were replaced with 100 ml of complete medium containing 10 ml of the CCK-8 solution. The plate was incubated for 1.5 h at 371C, and the absorbance at 450 nm was measured using a V max microplated spectrophotometer (Molecular Devices, Sunnyvale, CA). This was repeated each day for five days.
Clonogenic assay
Colony formation was evaluated using a soft agar clonogenic-forming assay. A volume of 0.5 ml of RPMI1640 containing 10% fetal bovine serum and 0.5% agar was plated on the bottom of 24-well plates. The plates were stored at 4 1C to allow the agar to freeze. A number of 500 cells per well were mixed with RPMI1640 containing 10% fetal bovine serum and 0.35% agar and plated onto the 24-well dishes that were prepared earlier (three wells per condition). The plates were then transferred at 371C. After 21-24 days, colonies were scored using a microscope. Colonies were also visualized by adding MTT (3-(4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide; Sigma-Aldrich, Poole, UK) at a concentration of 500 mg ml À1 . Colony formation for each condition was calculated in relation to values obtained for untreated control cells.
Nuclear morphology
Apoptosis was judged by nuclear condensation. Distilled slides were placed onto the surface of six-well plates, and Panc-1 cells were seeded onto the slides and allowed to adhere overnight. The cells were then transiently transfected with anti-ras, anti-akt2, anti-k þ a and negative plasmid using Lipofectamine2000 reagent. The serum-free medium was replaced with complete medium 6 h after transfection. At 4 days after transfection, slides were washed with PBS three times, and the cells were fixed with 4% formaldehyde for 10 min. The slides were washed again with PBS, and 0.1 ml of Hoechst 33342 at a concentration of 2 mg ml À1 was added to each slide and incubated at room temperature for 15 min. The slides were washed three times with PBS, and the cells were examined using a Nikon Eclipse TE2000 microscope and photographed.
Flow cytometric assay of apoptosis Panc-1 cells were seeded in 12-well plates and allowed to adhere overnight. The cells were transiently transfected with anti-ras, anti-akt2, anti-k þ a and negative plasmid using Lipofectamine2000 reagent. The serum-free medium was replaced with complete medium 6 h later. At 3 days after transfection, the cells were trypsinized and stained with Annexin V-FITC/PI (BD), according to the manufacturer's instructions. The cells were analyzed with a FACSCalibur flow cytometer (Beckon Dickinson, San Jose, CA) for the induction of apoptosis.
Xenograft studies in nude mice BALB/c male nude mice (nu/nu; 5 weeks of age) were obtained from Vitalriver (Beijing, China). Animal handling and experimental procedures were approved by the Peking Union Medical College animal experiments committee. Panc-1 cells were subcutaneously inoculated into the right dorsal region of mice to generate a primary tumor. Once tumor xenografts reached 50 mm 3 in size, mice were divided into six groups with six mice per treatment group. Tumors were injected with anti-ras, antiakt2, anti-k þ a, negative plasmid or PBS twice. A 25 kDa branched polyethyleneimine (PEI) was prepared as a stock solution of 0.045 g in 50 ml of 150 mM NaCl (10 mM in nitrogen residues). PEI-DNA transfections were performed at an N/P ratio of 10:1. An amount of 20 mg plasmid was mixed with the required amount of PEI in 150 mM NaCl in a 200 ml volume, followed by incubation at room temperature for 15 min. Animals were killed on day 40. Primary tumors were excised, measured and weighed. Tumor volumes were calculated according to the equation (width 2 Â length)/2.
Statistical analysis
Each experiment was repeated at least three times. Data were expressed as percentages of the control values (means ± s.e.m.). Data were submitted to a one-way analysis of variance followed by Dunnet's post hoc test. Differences were considered statistically significant at Po0.05.
Results
RNAi inhibits oncogenes K-ras and Akt2 at the mRNA and protein levels in Panc-1 cell line A number of pancreatic cancer cell lines were evaluated by immunoblotting to examine the protein levels of oncogenes K-ras and Akt2. The Panc-1 cell line showed the highest K-ras and Akt2 protein levels (Figure 1a) , and thus was selected for subsequent experiments.
To evaluate the efficiency of RNAi-mediated inhibition of K-ras and Akt2 in Panc-1 cells, reverse transcription-PCR, real-time PCR and western blotting were used to detect mRNA and protein levels. Panc-1 cells stably transfected with different RNAi plasmids (anti-ras, antiakt2, anti-k þ a, anti-a þ k and negative plasmid), as well as untreated Panc-1 cells, were harvested. The anti-ras and anti-akt2 RNAi plasmids specifically downregulated K-ras and Akt2 at both the mRNA (Figures 1c and 1d ) and protein (Figure 1b) levels. The anti-ras plasmid did not affect the Akt2 mRNA and protein levels, and the antiakt2 plasmid did not affect the K-ras mRNA and protein levels. The dual RNAi plasmids anti-k þ a and anti-a þ k lowered the K-ras and Akt2 mRNA and protein levels simultaneously, whereas the insertion sequence between the K-ras and Akt2 RNAi sequences in these plasmids (antik þ a and anti-aþ k) did not affect the interference efficacy. Furthermore, the insertion sequence alone (present in the negative plasmid), which does not target any known human gene, did not affect the mRNA and protein levels of K-ras and Akt2. When compared with untransfected cells, the RNAi plasmids anti-ras, anti-k þ a and anti-a þ k reduced the mRNA levels of K-ras by 79.7, 80.4 and 78.4%, respectively, whereas the anti-akt2 and negative plasmid had no effect on the K-ras mRNA (and protein) levels. The RNAi plasmids anti-akt2 and antik þ a, and anti-a þ k plasmids reduced the mRNA levels of Akt2 by 85.5, 87.2 and 86.3%, respectively, whereas the anti-ras and negative plasmid left the Akt2 mRNA (and protein) levels unchanged. (Figure 3a) .
To further evaluate the effect of the RNAi plasmids on inducing apoptosis, Annexin V labeling of externalized phosphatidylserine was carried out. Panc-1 cells transfected with anti-k þ a exhibited 45% Annexin V labeling, whereas cells transfected with anti-ras and anti-akt2 had only 17 and 12% Annexin V labeling, respectively (Figures 3b and c) . Panc-1 cells transfected with the negative plasmid or Lipofectamine2000 alone showed 5 and 2% Annexin V labeling, which was the same amount of Annexin V labeling as observed in untransfected Panc- Combined inhibition of both oncogenes can inhibit the phosphorylation levels of p-ERK and p-GSK and reduce the level of c-myc protein Downregulating the expression of oncogenes K-ras and Akt2 by RNAi should lead to changes in the Ras-and Akt2-mediated signaling pathways. As ERK-1/2 is the downstream effector of Ras in the Ras/MAPK signaling pathway and GSK-3 is the effector of Akt2 in the PI3K/ Akt signaling pathway, the phosphorylation level of these two proteins was examined. Inhibition of K-ras or Akt2 efficiently abolished p-ERK1/2 (Figure 4a ) or p-GSK-3 (Figure 4b ), whereas combined inhibition of K-ras and Akt2 simultaneously suppressed the phosphorylation levels of both ERK-1/2 and GSK-3.
c-myc is an oncoprotein related to growth, proliferation and apoptosis of tumor cells. As its expression is regulated by the Ras/MAPK and PI3K/Akt pathways, we investigated c-myc protein levels in the transfected Panc-1 cells. It shows that combined inhibition of K-ras and Akt2 caused a more significant reduction of c-myc protein level than inhibition of only one of the two oncogenes (Figure 4c ).
Combined inhibition of K-ras and Akt2 inhibited tumor growth in vivo more effectively than inhibition of either of the two genes alone We evaluated the effect of various RNAi plasmids on the growth of established tumors formed by Panc-1 cells in a subcutaneous nu/nu mouse model. Plasmids (anti-ras, anti-akt2, anti-k þ a and negative plasmid) were separately mixed with PEI and injected directly into tumors twice (day 1 and 7). In the fifth week after plasmid treatment, animals were killed and the tumors were dissected, photographed and weighed. The gross morphology of the tumor is shown (Figure 5a ). The antitumor effects of the RNAi plasmids are shown in Table 1 . A significant difference of tumor weight was observed between the anti-k þ a plasmid-treated group and the anti-ras-or anti-akt2-treated groups, whereas there were no significant differences in tumor weight among the antiakt2, negative plasmid, PEI alone treated groups and the untreated group (Figure 5b ; Table 1 ).
Discussion
Pancreatic cancer is a major challenge. Although the precise mechanism is not yet fully understood, the two pathways Ras/MAPK and PI3K/Akt have been found to be overactivated in most pancreatic cancer cell lines and tissues. Researchers have employed various methods to inhibit the two pathways in search of effective therapeutics. For example, inhibition of the oncogene K-ras was attempted with farnesyltransferase inhibitors and antisense RNA or RNAi technology, 12, 13 and inhibition of the oncogene Akt was tried with an Akt/protein kinase B signaling inhibitor-2 (API-2) and antisense RNA. 14, 15 Although many therapies appeared successful in laboratory, they showed limited efficacy in clinical trials. For example, blockers of K-ras or Ras activity, such as farnesyltransferase inhibitors, were not effective for patients with advanced forms of pancreatic cancer, 16 and rapamycin analogs, which inhibit signaling downstream of Akt, had limited clinical efficacy when used alone. 17 One potential strategy to improve the effectiveness of these therapeutic agents is to inhibit several targets simultaneously.
RNAi is a strong tool for silencing the function of specific endogenous genes. 18, 19 Thus far, most published cancer-related studies using RNAi focus on a single molecular target and not multiple genes. 20, 21 However, it Combined silencing of K-ras and Akt2 oncogenes XH Shi et al is now recognized that tumor growth depends on the activation of two or more oncogenes. Therefore, in this study, we used a plasmid-based RNAi system to evaluate whether simultaneously silencing two oncogenes, K-ras and Akt2, which are key players in two distinct signaling pathways, displays a greater effect on tumor inhibition than silencing a single oncogene. The experimental results both in vitro and in vivo confirmed our hypothesis that inhibiting two genes is better than inhibiting one. This is not unlike traditional cancer therapeutics where combination treatment is usually better than using a single agent, and thus provides a rational perspective for the development of molecular cancer therapeutics. Several mechanisms may contribute to the observation that combined silencing of two oncogenes K-ras and Akt2 achieved a synergistic effect in inhibiting proliferation of the pancreatic cancer cell line Panc-1 in vitro and in vivo. First, the Ras/MAPK and PI3K/Akt pathways are relatively parallel and cooperating pathways. Second, tumor dependence of oncogene signaling shifts from Ras signaling in tumor initiation to the PI3K/Akt pathway in tumor maintenance. Third, the BAD protein can integrate survival signaling by the Ras/MAPK and PI3K/Akt pathways in PTEN-deficient tumor cells. Finally, inhibition of the two signaling pathways can decrease the expression level of the oncogene c-myc.
Both the Ras/MAPK and PI3-kinase signaling pathways are activated in pancreatic cancer. 22 The magnitude or duration of PI3 kinase-initiated signals might be controlled not only by K-ras but also by other receptor and non-receptor tyrosine kinases, many of which are commonly overexpressed in pancreatic tumors. 23, 24 These include specific genes such as Akt2, which is amplified in about 20% of pancreatic tumors, and its phosphorylation level is higher in cell lines with no mutations or deletions of PTEN. 25 Although mutations or deletions of PTEN are not known to occur in the pancreatic ductal cancer cell line Panc-1, this result may be due to the functional status of PTEN (phosphorylation and interacting proteins) and the presence of other Akt regulators, such as CTMP, which could also influence the linear transmission of signals from PI3 kinase to Akt in Panc-1. 26 Some studies showed that Ras/MAPK and PI3K/Akt control parallel pathways in transformation mediated by v-Src. 27 Other studies show that combined inhibition of the PI3K/Akt and Ras/MAPK pathways with small molecules resulted in synergistic effects in inhibiting glioblastoma cells. 28 Therefore, the two pathways selected for this study were rational targets for the development of new targeted cancer molecular therapy strategies as they appear to be relatively parallel and cooperating pathways involved in proliferation and survival of pancreatic cancer cells. Ras signaling and the PI3K/Akt pathway appeared to be required primarily for tumor initiation and tumor maintenance, respectively. It has been observed that, in human cells Ras effectors MAPK, RalGEF and PI3K are required to initiate tumor growth. However, activation of the PI3K/Akt pathway replaced the role of Ras activation once tumors are formed. Thus, in many cases, as tumorigenesis progresses, cancer cells shift their oncogene dependence from Ras to the PI3K/Akt pathway.
The BAD protein plays an important role in mediating apoptotic signals in cells deprived of growth factors. BAD is a BH3 domain protein that, in its underphosphorylated form, induces apoptosis by dimerizing with and inactivating the antiapoptotic proteins Bcl-2 and Bcl-XL. 29 In the presence of growth factors, BAD is serine phosphorylated 30, 31 and bound to the 14-3-3 protein, and it is thus unable to interact with members of the Bcl-2 family. In many cells, BAD is predominantly phosphorylated on serine 112, a modification that is MAPK dependent. BAD is phosphorylated on other sites as well, including serine 136, an Akt-dependent site. 32 Inhibition of serine 112 or serine 136 phosphorylation alone was insufficient to cause a significant decrease in BAD-14-3-3 association. However, combined inhibition of phosphorylation at these two sites efficiently abrogates binding of BAD to 14-3-3. Therefore, it can be inferred that synergistic induction of Panc-1 apoptosis by combined inhibition of Ras/MAPK and PI3K/Akt signaling is, at least partially, due to activation of the BAD protein. 33 This could explain the apoptosis results obtained in this study.
The c-myc transcription factor is a powerful regulator of cell growth, proliferation, differentiation and apoptosis, and its constitutive expression is key to the genesis of many cancers. 34 In addition, c-myc is amplified and overexpressed in primary and metastatic pancreatic ductal adenocarcinomas. 35, 36 There are two phosphorylation sites, serine 62 and threonine 58, in the N terminus of c-myc. Serine 62 is a target of ERK, and threonine 58 is a target of glycogen synthase kinase (GSK-3). Serine 62 phosphorylation stabilizes c-myc, whereas threonine 58 phosphorylation destabilizes c-myc. [37] [38] [39] Inhibiting the oncogene K-ras can promote c-myc protein destabilization through ERK-mediated dephosphorylation of serine 62. 40 However, Akt phosphorylates and inhibits GSK-3, so inhibition of the Akt2 also facilitates c-myc destabilization through GSK3-mediated phosphorylation of threonine 58. 24 Thus, combined silencing of the Ras/ ERK and PI3K/Akt pathways can cooperate to downregulate the level of c-myc, as is confirmed by our results.
In summary, this study employed plasmid-based RNAi technology to simultaneously silence two oncogenes. This dual silencing approach achieved better tumor inhibition than silencing each oncogene alone. Unlike the cytotoxic chemotherapy agents that often share similar toxicities, limiting their use in combination, 41 synergistically inhibiting two key oncogenes with a plasmid-based RNAi strategy could achieve intended effects efficiently and specifically in vitro and in vivo. This result may offer potential opportunities for clinical cancer therapy.
